171 related articles for article (PubMed ID: 30915617)
1. Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer.
Ray P; Nair G; Ghosh A; Banerjee S; Golovko MY; Banerjee SK; Reindl KM; Mallik S; Quadir M
J Cell Commun Signal; 2019 Sep; 13(3):407-420. PubMed ID: 30915617
[TBL] [Abstract][Full Text] [Related]
2. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
[TBL] [Abstract][Full Text] [Related]
3. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Ray P; Confeld M; Borowicz P; Wang T; Mallik S; Quadir M
Colloids Surf B Biointerfaces; 2019 Feb; 174():126-135. PubMed ID: 30447521
[TBL] [Abstract][Full Text] [Related]
4. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
[TBL] [Abstract][Full Text] [Related]
6. Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy.
Fan Y; Wang Q; Lin G; Shi Y; Gu Z; Ding T
Acta Biomater; 2017 Oct; 62():257-272. PubMed ID: 28859899
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis.
Chen X; Tao Y; He M; Deng M; Guo R; Sheng Q; Wang X; Ren K; Li T; He X; Zang S; Zhang Z; Li M; He Q
Theranostics; 2021; 11(18):8692-8705. PubMed ID: 34522207
[No Abstract] [Full Text] [Related]
8. Fabrication of dopamine conjugated with protein @metal organic framework for targeted drug delivery: A biocompatible pH-Responsive nanocarrier for gemcitabine release on MCF‑7 human breast cancer cells.
Abd Al-Jabbar S; Atiroğlu V; Hameed RM; Guney Eskiler G; Atiroğlu A; Deveci Ozkan A; Özacar M
Bioorg Chem; 2022 Jan; 118():105467. PubMed ID: 34781115
[TBL] [Abstract][Full Text] [Related]
9. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Karaca M; Dutta R; Ozsoy Y; Mahato RI
Mol Pharm; 2016 Jun; 13(6):1822-32. PubMed ID: 26981724
[TBL] [Abstract][Full Text] [Related]
10. Dendritic Polyglycerol-Derived Nano-Architectures as Delivery Platforms of Gemcitabine for Pancreatic Cancer.
Ray P; Ferraro M; Haag R; Quadir M
Macromol Biosci; 2019 Jul; 19(7):e1900073. PubMed ID: 31183964
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer.
Li YJ; Wu JY; Wang JM; Hu XB; Cai JX; Xiang DX
Acta Biomater; 2020 Jan; 101():519-530. PubMed ID: 31629893
[TBL] [Abstract][Full Text] [Related]
12. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
[TBL] [Abstract][Full Text] [Related]
14. Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.
Sun J; Wan Z; Chen Y; Xu J; Luo Z; Parise RA; Diao D; Ren P; Beumer JH; Lu B; Li S
Acta Biomater; 2020 Apr; 106():289-300. PubMed ID: 32004652
[TBL] [Abstract][Full Text] [Related]
15. Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer.
Uz M; Kalaga M; Pothuraju R; Ju J; Junker WM; Batra SK; Mallapragada S; Rachagani S
J Control Release; 2019 Jan; 294():237-246. PubMed ID: 30576747
[TBL] [Abstract][Full Text] [Related]
16. Enhancing pancreatic ductal adenocarcinoma (PDAC) therapy with targeted carbon nano-onion (CNO)-mediated delivery of gemcitabine (GEM)-derived prodrugs.
Bartkowski M; Bincoletto V; Salaroglio IC; Ceccone G; Arenal R; Nervo S; Rolando B; Riganti C; Arpicco S; Giordani S
J Colloid Interface Sci; 2024 Apr; 659():339-354. PubMed ID: 38176243
[TBL] [Abstract][Full Text] [Related]
17. Surface-enhanced Raman scattering investigation of targeted delivery and controlled release of gemcitabine.
Santiago T; DeVaux RS; Kurzatkowska K; Espinal R; Herschkowitz JI; Hepel M
Int J Nanomedicine; 2017; 12():7763-7776. PubMed ID: 29123391
[TBL] [Abstract][Full Text] [Related]
18. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling.
Wang B; Shen C; Li Y; Zhang T; Huang H; Ren J; Hu Z; Xu J; Xu B
Onco Targets Ther; 2019; 12():5751-5765. PubMed ID: 31410021
[No Abstract] [Full Text] [Related]
19. Thermo- and pH-responsive targeted lipid-coated mesoporous nano silica platform for dual delivery of paclitaxel and gemcitabine to overcome HER2-positive breast cancer.
Nasri N; Saharkhiz S; Dini G; Yousefnia S
Int J Pharm; 2023 Dec; 648():123606. PubMed ID: 37972671
[TBL] [Abstract][Full Text] [Related]
20. An Amphiphilic PEGylated Peptide Dendron-Gemcitabine Prodrug-Based Nanoagent for Cancer Therapy.
Li N; Duan Z; Wang L; Guo C; Zhang H; Gu Z; Gong Q; Luo K
Macromol Rapid Commun; 2021 Jun; 42(12):e2100111. PubMed ID: 33871122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
